Jun 24, 2026 – 1.28pmRecce Pharmaceuticals, a late-stage clinical biotech company developing therapies to address antimicrobial-resistant superbugs, has launched a $10 million capital raising to complete a phase of its clinical trials and support its new licensing agreement.James Graham, chief executive of Recce Pharmaceuticals. Michael Amendolia Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones.Kanika Sood is a journalist based in Sydney who writes for the Street Talk column.Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber?
Recce Pharmaceuticals seeks $10m capital injection
Sole lead manager Ord Minnett was offering new shares at 40¢ a pop on Wednesday, representing a 13 per cent discount to the last close price.
140 words~1 min read
